TY - JOUR
T1 - Human assembloids recapitulate periportal liver tissue in vitro
AU - Yuan, Lei
AU - Dawka, Sagarika
AU - Kim, Yohan
AU - Liebert, Anke
AU - Rost, Fabian
AU - Arnes-Benito, Robert
AU - Baenke, Franziska
AU - Götz, Christina
AU - Tsang, David Long Hin
AU - Schuhmann, Andrea
AU - Shevchenko, Anna
AU - Rezende de Castro, Roberta
AU - Kim, Seunghee
AU - Sljukic, Aleksandra
AU - Dowbaj, Anna M.
AU - Shevchenko, Andrej
AU - Seehofer, Daniel
AU - Choi, Dongho
AU - Damm, Georg
AU - Stange, Daniel E.
AU - Huch, Meritxell
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2026/2/12
Y1 - 2026/2/12
N2 - The development of complex multicellular human in vitro systems holds great promise for modelling disease and advancing drug discovery and tissue engineering1. In the liver, despite the identification of key signalling pathways involved in hepatic regeneration2,3, in vitro expansion of human hepatocytes directly from fresh patient tissue has not yet been achieved, limiting the possibility of modelling liver composite structures in vitro. Here we first developed human hepatocyte organoids (h-HepOrgs) from 28 different patients. Patient-derived hepatocyte organoids sustained long-term expansion of hepatocytes in vitro and maintained patient-specific gene expression and bile canaliculus features and function of the in vivo tissue. After transplantation, expanded h-HepOrgs rescued the phenotype of a mouse model of liver disease. By combining h-HepOrgs with portal mesenchyme and our previously published cholangiocyte organoids4, 5–6, we generated patient-specific periportal liver assembloids that retain the histological arrangement, gene expression and cell interactions of periportal liver tissue, with cholangiocytes and mesenchyme embedded in the hepatocyte parenchyma. We leveraged this platform to model aspects of biliary fibrosis. Our human periportal liver assembloid system represents a novel in vitro platform to investigate human liver pathophysiology, accelerate drug development, enable early diagnosis and advance personalized medicine.
AB - The development of complex multicellular human in vitro systems holds great promise for modelling disease and advancing drug discovery and tissue engineering1. In the liver, despite the identification of key signalling pathways involved in hepatic regeneration2,3, in vitro expansion of human hepatocytes directly from fresh patient tissue has not yet been achieved, limiting the possibility of modelling liver composite structures in vitro. Here we first developed human hepatocyte organoids (h-HepOrgs) from 28 different patients. Patient-derived hepatocyte organoids sustained long-term expansion of hepatocytes in vitro and maintained patient-specific gene expression and bile canaliculus features and function of the in vivo tissue. After transplantation, expanded h-HepOrgs rescued the phenotype of a mouse model of liver disease. By combining h-HepOrgs with portal mesenchyme and our previously published cholangiocyte organoids4, 5–6, we generated patient-specific periportal liver assembloids that retain the histological arrangement, gene expression and cell interactions of periportal liver tissue, with cholangiocytes and mesenchyme embedded in the hepatocyte parenchyma. We leveraged this platform to model aspects of biliary fibrosis. Our human periportal liver assembloid system represents a novel in vitro platform to investigate human liver pathophysiology, accelerate drug development, enable early diagnosis and advance personalized medicine.
UR - https://www.scopus.com/pages/publications/105025160118
U2 - 10.1038/s41586-025-09884-1
DO - 10.1038/s41586-025-09884-1
M3 - Article
C2 - 41407857
AN - SCOPUS:105025160118
SN - 0028-0836
VL - 650
SP - 438
EP - 449
JO - Nature
JF - Nature
IS - 8101
ER -